Electromed (ELMD)
Prescription SmartVest airway-clearance systems with direct homecare reimbursement and support.
Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) Surpasses Q4 Earnings Estimates
Electromed, Inc. (ELMD) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share a year ago.
Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results.
Electromed Announces CEO's Planned Retirement
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed Announces CEO's Planned Retirement.
Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026.
Electromed (ELMD) Is a Great Choice for 'Trend' Investors, Here's Why
Electromed (ELMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why Momentum in Electromed (ELMD) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Electromed (ELMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Electromed: Strong Margins, Strong Growth, Large Runway
Electromed is rated 'buy' due to accelerating growth, margin expansion, and a large underpenetrated bronchiectasis market. ELMD benefits from a new CMS rule and a recently approved bronchiectasis drug, both driving increased disease awareness and streamlined clinician adoption. Gross margin improved to 78.5%, operating margin rose to 20.4%, and net income reached a record $3.0 million in Q3 FY 2026.
Is Electromed (ELMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
Electromed (ELMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Best Momentum Stocks to Buy for June 2nd
GOLD, ELMD and TPR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 2nd, 2026.
Electromed, Inc. (ELMD) Hits Fresh High: Is There Still Room to Run?
Electromed (ELMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Medical Instrument Stocks Exploring GenAI to Tackle Industry Woes
GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.
Electromed, Inc. (ELMD)'s Technical Outlook is Bright After Key Golden Cross
Electromed, Inc. (ELMD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ELMD's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Electromed (ELMD) is an Incredible Growth Stock: 3 Reasons Why
Electromed (ELMD) possesses solid growth attributes, which could help it handily outperform the market.
What Makes Electromed (ELMD) a Good Fit for 'Trend Investing'
Electromed (ELMD) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
All You Need to Know About Electromed (ELMD) Rating Upgrade to Strong Buy
Electromed (ELMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Electromed, Inc. (ELMD) Q3 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) Q3 2026 Earnings Call Transcript
Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter.
Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026.
3 Reasons Growth Investors Will Love Electromed (ELMD)
Electromed (ELMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.